Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
MGTX · Why this verdict
Why MeiraGTx Holdings (MGTX) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
MGTX clears the V9 asymmetry gate with large modeled upside and positive free cash flow despite GAAP losses, but overbought momentum, a string of earnings misses, and notable insider selling temper the setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company generates positive free cash flow despite a GAAP loss, with a 56% FCF margin and 3.5% FCF yield, though it fails the Rule of 40 test at -28. Quality breakdown | The Rule of 40 score should improve toward positive territory as growth and FCF margin combine more favorably. | →Stable |
| CounterA no-moat quality flag alongside the Rule of 40 failure suggests the FCF strength may not translate into durable competitive advantage. | ||
The V9 engine passes the asymmetry gate at a 5.1 ratio, with modeled upside of 76.6% to the analyst-target take-profit against a 15% modeled downside. Reward-to-risk math | The asymmetry ratio should remain elevated above 1.5 as the stock progresses toward the analyst target. | →Stable |
| CounterLight analyst coverage at a level of 8.0 dampens confidence in the price target driving this asymmetry calculation. | ||
The company has missed earnings estimates in 3 of the last 4 quarters, including misses of -27.4% and -26.5%, despite one large beat of 130.7%. Bear case | The beat rate should improve to at least 2 of the next 4 quarters as execution stabilizes. | ↑Improving |
| CounterThe one large beat shows the business can outperform sharply, and biotech earnings are inherently lumpy around trial and program milestones. | ||
Momentum is strong but the stock is overbought with an RSI of 84 while trading just 0.1% below its 52-week high. Momentum breakdown | RSI should cool from 84 toward a more sustainable 50-70 range without a sharp price reversal. | ↑Improving |
| CounterStrong volume accumulation, with a rising OBV reading, suggests genuine buying interest rather than an unsustainable spike. | ||
Insiders sold a notable $1,399,767, or 0.109% of market cap, over the trailing 90 days, driving a bearish insider signal. Insider breakdown | Insider selling should moderate or insider buying should resume, shifting the signal away from bearish. | ↑Improving |
| CounterInsider sales at biotech companies are frequently tied to pre-scheduled selling plans (Rule 10b5-1) rather than a negative view of near-term prospects. | ||
The company generates positive free cash flow despite a GAAP loss, with a 56% FCF margin and 3.5% FCF yield, though it fails the Rule of 40 test at -28.
→StableQuality breakdown
- Expectation
- The Rule of 40 score should improve toward positive territory as growth and FCF margin combine more favorably.
CounterA no-moat quality flag alongside the Rule of 40 failure suggests the FCF strength may not translate into durable competitive advantage.
The V9 engine passes the asymmetry gate at a 5.1 ratio, with modeled upside of 76.6% to the analyst-target take-profit against a 15% modeled downside.
→StableReward-to-risk math
- Expectation
- The asymmetry ratio should remain elevated above 1.5 as the stock progresses toward the analyst target.
CounterLight analyst coverage at a level of 8.0 dampens confidence in the price target driving this asymmetry calculation.
The company has missed earnings estimates in 3 of the last 4 quarters, including misses of -27.4% and -26.5%, despite one large beat of 130.7%.
↑ImprovingBear case
- Expectation
- The beat rate should improve to at least 2 of the next 4 quarters as execution stabilizes.
CounterThe one large beat shows the business can outperform sharply, and biotech earnings are inherently lumpy around trial and program milestones.
Momentum is strong but the stock is overbought with an RSI of 84 while trading just 0.1% below its 52-week high.
↑ImprovingMomentum breakdown
- Expectation
- RSI should cool from 84 toward a more sustainable 50-70 range without a sharp price reversal.
CounterStrong volume accumulation, with a rising OBV reading, suggests genuine buying interest rather than an unsustainable spike.
Insiders sold a notable $1,399,767, or 0.109% of market cap, over the trailing 90 days, driving a bearish insider signal.
↑ImprovingInsider breakdown
- Expectation
- Insider selling should moderate or insider buying should resume, shifting the signal away from bearish.
CounterInsider sales at biotech companies are frequently tied to pre-scheduled selling plans (Rule 10b5-1) rather than a negative view of near-term prospects.
Per-dimension breakdown
Quality
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Current ratio | 2.2 |
| FCF quality | 10.0 |
| Moat | 5.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸FCF-positive despite GAAP loss (FCF margin 56%, FCF yield 3.7%)
- ▸No competitive moat
- ▸Rule of 40: -28 (fail)
Growth
5.0/10data confidence 50%Momentum
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 7.8 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.7 |
| Price target | 10.0 |
| erm sentiment | 5.2 |
- ▸Light analyst coverage (7.0) — signal dampened
- ▸Analyst upside: 125%
Insider
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Notable insider selling — $1,678,570 (0.139% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.6 |
| quality rank | 0.0 |
| growth rank | 0.7 |
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.9 |
| support resistance | 1.6 |
| 52w position | 7.0 |
| gap | 5.0 |
Risk (lower is worse)
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.8 |
| days to cover | 7.6 |
| volatility | 2.3 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 6.0 |
- ▸Elevated put/call: 2.00
- ▸High IV: 208%
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 1B/3M
- ▸Earnings in 1 days
How the verdict was assembled
Engine trigger
Earnings in 1 day. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (7)
- MOMENTUM:6.4>=5.5
- ASYMMETRY:7.2>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:1d<=7d
Warning (0)
none
Reward-to-Risk
7.16
Upside
+95.7%
Downside
13.4%
Sizing output
STARTER
SetupBreakout — Golden cross, above all MAs, RSI 62, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings in 1 day. Wait until post-earnings. The 10-dimension scores remain Sentiment at 7.8 (strongest), but EARNINGS_PROXIMITY:1d<=7d also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Sentiment at 7.8, Momentum at 6.4, and Insider at 5.5; the weakest are Peer rank at 2.3, Technical at 3.6, and Risk (lower is worse) at 3.8. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 7.16 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Asymmetry Large Modeled Upside
Trip ifAsymmetry ratio falls below 1.5, breaking the V9 gate that currently passes at 5.1.
- P2Consecutive Earnings Misses
Trip ifEarnings beat rate rises to at least 3 of the next 4 quarters.
- P3Overbought Momentum Near 52 Week High
Trip ifRSI falls below 50 alongside a price decline of more than 15% from the current level.
- P4Notable Insider Selling
Trip ifInsider signal flips to bullish with net buying that exceeds $500,000 over a 90-day window.
- P5Cash Flow Positive Despite Gaap Loss
Trip ifFree cash flow margin falls below 0%, ending the FCF-positive-despite-GAAP-loss thesis.